CAJ | 학술논문

目的：评价丹参酮ⅡA联合重组人脑钠肽（ rhBNP ）治疗充血性心力衰竭的临床疗效及安全性。方法80例充血性心力衰竭患者随机分为对照组40例与试验组40例，2组均给予常规治疗，对照组静脉滴注丹参注射液10 mL，每日1次，试验组静脉滴注丹参酮ⅡA磺酸钠注射液60 mg，每日1次，同时联合静脉滴注rhBNP 1.5μg· kg -1，均连续用药1周。比较2组临床疗效、治疗前后血浆脑钠肽（ BNP）、一氧化氮水平变化、超声心动相关指标变化以及不良反应发生情况。结果治疗后，对照组临床总有效率为65.00％，显著低于试验组的90.00％（P＜0.05）。2组治疗后血浆一氧化氮、心排血量（CO）及左心室射血分数（ LVEF）均显著升高，且试验组显著高于对照组（ P＜0.05）；血浆脑钠肽、左心室收缩末期容积（LVESV）、左心室舒张末期内径（LVESD）均显著降低，且试验组显著小于对照组（ P＜0.05）。对照组不良反应发生率为10.00％，试验组为7.50％，差异无统计学意义（ P>0.05）。结论丹参酮ⅡA联合rhBNP治疗充血性心力衰竭的临床疗效显著，安全性高。
목적：평개단삼동ⅡA연합중조인뇌납태（ rhBNP ）치료충혈성심력쇠갈적림상료효급안전성。방법80례충혈성심력쇠갈환자수궤분위대조조40례여시험조40례，2조균급여상규치료，대조조정맥적주단삼주사액10 mL，매일1차，시험조정맥적주단삼동ⅡA광산납주사액60 mg，매일1차，동시연합정맥적주rhBNP 1.5μg· kg -1，균련속용약1주。비교2조림상료효、치료전후혈장뇌납태（ BNP）、일양화담수평변화、초성심동상관지표변화이급불량반응발생정황。결과치료후，대조조림상총유효솔위65.00％，현저저우시험조적90.00％（P＜0.05）。2조치료후혈장일양화담、심배혈량（CO）급좌심실사혈분수（ LVEF）균현저승고，차시험조현저고우대조조（ P＜0.05）；혈장뇌납태、좌심실수축말기용적（LVESV）、좌심실서장말기내경（LVESD）균현저강저，차시험조현저소우대조조（ P＜0.05）。대조조불량반응발생솔위10.00％，시험조위7.50％，차이무통계학의의（ P>0.05）。결론단삼동ⅡA연합rhBNP치료충혈성심력쇠갈적림상료효현저，안전성고。
Objective To evaluate the efficacy and safety of sulfotanshi-none combined with recombinant human brain natriuretic peptide ( rhBNP) in the treatment of congestive heart failure ( CHF).Methods A total of 80 cases with CHF included in this study were dividing into control group and experiment group with each 40 cases.The patients in the both groups were give regular treatment .Patients in the control group were given Danshen injection 10 mL by intravenous drip with 1 week and patients in the experiment group revieved sulfotanshinone sodium injection 60 mg, intravenous drip qd plus rhBNP 1.5 μg · kg -1 in travenous drip with 1 week. The clinical efficacy , brain natriuretic peptide(BNP), nitric oxide(NO) and heart function were compared be-tween the two groups ( P<0.05 ) .Results The clinical efficacy in ex-periment group was 90.00%, which significant higher than that in con-trol group ( 65.00%, P <0.05 ).The serum NO, cardiac outcome (CO), and left ventricular ejection fraction ( LVEF) all elevated in the two groups with experiment group much higher than the control group (P<0.05).The serum level of BNP, left ventricular end-systolic vol-ume ( LVESV ) and left ventricular end -systolic dimension ( LVESD )significant decreased after treatment with experiment group much lower than the control group ( P<0.05 ).The adverse drug reactions was not statistically different between the two groups ( P>0.05 ) .Conclusion Sulfotanshinone com-bined with rhBNP in the treatment of CHF was effective with high safety .